## **Contents**

## Part I The Patient

1	Paediatric Development: Anatomy. Age, Weight, Body Surface and Stature, Organ Development Hannah Batchelor	3
2	Pediatric Development: Physiology. Enzymes, Drug Metabolism, Pharmacokinetics and Pharmacodynamics Geert 't Jong	Ģ
3	Developmental Changes in the Processes Governing Oral Drug Absorption	25
4	Paediatric Development: Gastrointestinal Hannah Batchelor	. 43
5	How to Estimate the Dose to Be Given for the First Time to Pediatric Patients Gerard Greig	55
6	The Clinical Relevance of Pediatric Formulations	69
Par	t II Formulating for Children I, the Oral Route	
7	General Considerations for Pediatric Oral Drug Formulation Valentina Shakhnovich and Susan M. Abdel-Rahman	89
8	Orosensory Perception	105

x

9	Flavor Is Not Just Taste: Taste Concealing	123
10	Liquid Formulations	141
11	Paediatric Solid Formulations	153
12	Semi-solid Formulations Irwin C. Jacobs	171
13	The Challenge of Automated Compounding	181
14	Pediatric Formulations in Clinical Testing and the Challenge of Final Market Formulation	193
15	Buccal/Sublingual Drug Delivery for the Paediatric Population	205
Par	t III Formulating for Children II, Non-oral Routes	
16	Topical and Transdermal William J. McAuley, Matthew Traynor, and Marc B. Brown	219
17	Parenteral Liquids for Intravenous and Transdermal Use Utpal U. Shah and Matthew Roberts	239
18	The Challenges of Paediatric Pulmonary Drug Delivery  Darragh Murnane and Marc B. Brown	253
19	Nasal, Ocular and Otic Drug Delivery Hannah Batchelor	273
20	Rectal Drug Delivery	303
21	Intraosseous Infusions in Infants and Neonates	311
Par	t IV Compounding	
22	Compounding for Children: The Compounding PharmacistLinda F. McElhiney	329

Contents xi

Par	t V Materials	
23	Food Ingredients	33′
24	Excipients and Active Pharmaceutical Ingredients	347
Par	t VI Clinical Development and Regulatory Aspects	
25	Clinical Testing in Children	365
26	Pediatric Formulations and Dosage Forms and Future Opportunities: Impact of Regulations in the USA and Implementation of Quality by Design	377
27	Paediatric Pharmaceutical Legislation and Its Impact on Adult and Paediatric Drug Development: The EU Regulatory View	395
28	Pediatric Pharmaceutical Legislation in the USA and EU and Their Impact on Adult and Pediatric Drug Development	405
29	Checks and Balances in the EU: The Role of the European Ombudsman, with a Focus on the Paediatric Regulation	421
Par	t VII Concluding Remarks: The Future of Pediatric Formulations	
30	The Dangerous Business of Predicting the Future  Daniel Bar-Shalom, Hannah Batchelor,  Linda F. McElhiney, and Klaus Rose	429
Abo	out the Authors	433
T J.		125